<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653546</url>
  </required_header>
  <id_info>
    <org_study_id>AZD3759-003</org_study_id>
    <nct_id>NCT03653546</nct_id>
  </id_info>
  <brief_title>First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases</brief_title>
  <acronym>BM</acronym>
  <official_title>A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha Biopharma (Jiangsu) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha Biopharma (Jiangsu) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first-line treatment with single agent AZD3759 results in superior Progression Free&#xD;
      Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine&#xD;
      Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell&#xD;
      lung cancer (NSCLC) with Central Nervous System (CNS) metastasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and&#xD;
      safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients&#xD;
      with advanced EGFR mutation positive NSCLC with CNS metastases.&#xD;
&#xD;
      Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-naïve advanced&#xD;
      NSCLC and documented intracranial disease will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS assessed by Blinded Independent Central Radiological</measure>
    <time_frame>36 months</time_frame>
    <description>To assess if first line treatment with AZD3759 results in significant PFS efficacy compared to Gefitinib or Erlotinib as determined by Blinded Independent Central Radiological (BICR) review using RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS assess by investigator</measure>
    <time_frame>36 months</time_frame>
    <description>Investigator assessment of PFS using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS (iPFS) assessed by investigator</measure>
    <time_frame>36 months</time_frame>
    <description>Intracranial PFS (iPFS) assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS (iPFS) assessed by BICR</measure>
    <time_frame>36 months</time_frame>
    <description>Intracranial PFS (iPFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial PFS (ePFS) assessed by investigator</measure>
    <time_frame>36 months</time_frame>
    <description>Extracranial PFS (ePFS) assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial PFS (ePFS) assessed by BICR</measure>
    <time_frame>36 months</time_frame>
    <description>Extracranial PFS (ePFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR） assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Objective Response Rate (ORR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Disease Control Rate (DCR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Duration of Response (DoR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall ORR assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Overall ORR assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall DCR assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Overall DCR assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall DoR assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Overall DoR assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for Intracranial lesions assessed by investigator using RANO-BM</measure>
    <time_frame>36 months</time_frame>
    <description>ORR for Intracranial lesions assessed by investigator using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR for Intracranial lesions assessed by investigator using RANO-BM</measure>
    <time_frame>36 months</time_frame>
    <description>DCR for Intracranial lesions assessed by investigator using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR for Intracranial lesions assessed by investigator using RANO-BM</measure>
    <time_frame>36 months</time_frame>
    <description>DoR for Intracranial lesions assessed by investigator using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).</measure>
    <time_frame>36 months</time_frame>
    <description>The 30-items questionnaire measures cancer patients' functioning and symptoms. The scale range of EORTC QLQ-C30 is 30-126. Lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire BN20 (EORTC QLQ-BN20).</measure>
    <time_frame>36 months</time_frame>
    <description>The 20-items questionnaire was used among brain cancer patients. The scale range of EORTC BN20 is 20-80. Lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)</measure>
    <time_frame>36 months</time_frame>
    <description>Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological function improvement rate assessed by RANO-BM criteria</measure>
    <time_frame>36 months</time_frame>
    <description>Neurological function improvement rate assessed by RANO-BM criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and Diastolic Blood Pressure assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Systolic and Diastolic Blood Pressure assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Pulse rate to assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Body temperature assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assess by BICR</measure>
    <time_frame>36 months</time_frame>
    <description>Blinded Independent Central Radiological (BICR) assessment of PFS using modified RECIST 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pop-PK analysis</measure>
    <time_frame>36 months</time_frame>
    <description>Population pharmacokinetic analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Exposure-Response analysis</measure>
    <time_frame>36months</time_frame>
    <description>explore the correlation in exposure and efficacy, exposure and safety in the Study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">492</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>EGFR Gene Mutation</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>AZD3759 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3759 group will receive a 200 mg twice daily dose of AZD3759</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib or Gefitinib Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3759</intervention_name>
    <description>Advanced Non-Small Cell Lung Cancer (NSCLC) with CNS metastases.</description>
    <arm_group_label>AZD3759 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>SoC EGFRTKI Erlotinib 150 mg PO Q.D</description>
    <arm_group_label>Erlotinib or Gefitinib Group</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>SoC EGFRTKI Gefitinib 250 mg PO Q.D</description>
    <arm_group_label>Erlotinib or Gefitinib Group</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Properly completed patient informed consent&#xD;
&#xD;
          2. Male or female aged at least 18 years&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR&#xD;
             mutations including L858R and/or Exon19Del. EGFR mutation status will be determined by&#xD;
             local or central laboratory testing on tumour tissue or plasma utilizing a validated&#xD;
             methodology which has been approved by the regulatory authority.&#xD;
&#xD;
          4. No prior treatment with chemotherapy, EGFR-TKIs, or biological therapies that are&#xD;
             considered first line treatment for advanced NSCLC.&#xD;
&#xD;
          5. All patients must have a documented diagnosis of advanced (Stage IV) NSCLC with&#xD;
             Magnetic Resonance Imaging (MRI) documented CNS metastases that include brain&#xD;
             metastases (BM). BM + patients with co- existent leptomeningeal involvement are&#xD;
             eligible for the study.&#xD;
&#xD;
          6. Eligible patients are not candidates for definitive surgical resection or radiation of&#xD;
             all lesions in the opinion of the treating physician.&#xD;
&#xD;
          7. All patients must be stable without any systemic (oral or parenteral) corticosteroid&#xD;
             or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled&#xD;
             non-absorbable and topical corticosteroid use are permitted as indicated.&#xD;
&#xD;
          8. Patients may have prior placement of a properly functioning CNS shunt or Ommaya&#xD;
             reservoir.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no&#xD;
             deterioration over the previous 2 weeks.&#xD;
&#xD;
         10. Women of child-bearing potential and male subjects shall agree to take medically&#xD;
             acceptable contraception measures while on study treatment and for 3 months following&#xD;
             completion of study treatment. All women of child-bearing potential must have a&#xD;
             negative blood pregnancy test at screening.&#xD;
&#xD;
         11. (a) For Patients with measurable CNS lesions must have AT LEAST ONE site of CNS&#xD;
             lesion, which was not previously irradiated, that can be accurately measured at&#xD;
             baseline as ≥ 10 mm in the longest diameter by MRI and which is suitable for accurate&#xD;
             repeated measurements. Measurable extracranial disease is not required. (b) For&#xD;
             Patients with non-measurable CNS lesions must have AT LEAST ONE extracranial lesion,&#xD;
             which has not been previously irradiated, within the screening period that can be&#xD;
             accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes&#xD;
             which must have short axis ≥ 15 mm) by CT/MRI and are suitable for accurate repeated&#xD;
             measurement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Ju Ahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qing Zhou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Yichang</city>
        <state>Hubei</state>
        <zip>443003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214062</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site 0123</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>261000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Shenyang</city>
        <state>Shenyang</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>311100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Chongqing</city>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Site</name>
      <address>
        <city>Chungbuk</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Gyeongsang</city>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Seoul</city>
        <zip>05368</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea site</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiwan site</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiwan site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiwan site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiwan site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Barajas RF Jr, Cha S. Imaging diagnosis of brain metastasis. Prog Neurol Surg. 2012;25:55-73. doi: 10.1159/000331174. Epub 2012 Jan 6. Review.</citation>
    <PMID>22236668</PMID>
  </reference>
  <reference>
    <citation>Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007 Mar 15;13(6):1663-74. Review.</citation>
    <PMID>17363519</PMID>
  </reference>
  <reference>
    <citation>Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468.</citation>
    <PMID>18172267</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Nervous System Metastases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>EGFR</keyword>
  <keyword>Exon 19Del</keyword>
  <keyword>L858R</keyword>
  <keyword>Lung Neoplasm</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

